Mauna Kea Technologies
Develops technology for optical biopsies.
Launch date
Employees
Market cap
$25.0m
Enterprise valuation
$66m (Public information from Sep 2024)
Share price
€0.37 MKEA.PA
Company register number 431268028
Paris Île-de-France (HQ)
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 7.0m | 8.0m | 7.0m | 10.5m | 7.1m | 8.2m | 9.4m |
% growth | - | 14 % | (13 %) | 50 % | (32 %) | 15 % | 15 % |
EBITDA | (11.0m) | (9.0m) | (8.0m) | 13.4m | (6.3m) | (5.6m) | (4.6m) |
% EBITDA margin | (157 %) | (113 %) | (114 %) | 128 % | (89 %) | (68 %) | (49 %) |
Profit | (13.0m) | (13.0m) | (11.0m) | (3.7m) | (9.0m) | (8.3m) | (7.5m) |
% profit margin | (186 %) | (163 %) | (157 %) | (36 %) | (127 %) | (101 %) | (80 %) |
EV / revenue | 8.4x | 6.3x | 6.4x | 4.3x | 8.5x | 8.4x | 8.1x |
EV / EBITDA | -5.3x | -5.6x | -5.6x | 3.3x | -9.6x | -12.2x | -16.6x |
R&D budget | 3.2m | 3.3m | 4.1m | - | - | - | - |
R&D % of revenue | 46 % | 41 % | 58 % | - | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
$30.0m | Series B | ||
N/A | N/A | IPO | |
* | €7.0m | Debt | |
N/A | $8.4m | Post IPO Equity | |
* | €6.0m | Post IPO Debt | |
* | N/A | Post IPO Equity | |
Total Funding | $30.0m |
Related Content
Recent News about Mauna Kea Technologies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.